UCB has announced its financial results for the first nine months of 2017, during which it reported a nine percent year-on-year increase in revenues.
The company's revenue total for the first three quarters came to 3.3 billion euros (2.94 billion pounds), with sales of its main products totalling 2.6 billion euros - up by 15 percent on last year.
“UCB has announced strong financial results for the first nine months of 2017, allowing the company to increase its estimates for the full year.“
Core drivers of this continued growth were key brands such as Cimzia, Vimpat, Keppra, Briviact and Neupro, with Briviact approved as an epilepsy monotherapy in the US, while Vimpat was approved as a monotherapy in Japan and for children as an add-on therapy in the EU.
Jean-Christophe Tellier, chief executive officer of UCB, said: "UCB has delivered a good first nine months of the year 2017. This good performance allows us to increase our earnings guidance for 2017."
For the full year, the company now expects to achieve a revenue total of between 4.4 billion and 4.5 billion euros, while core earnings per share in the range of 4.10 to 4.50 euros have been forecast.
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical